DECREASED METHIONINE ADENOSYLTRANSFERASE ACTIVITY IN ERYTHROCYTES OF PATIENTS WITH DEMENTIA DISORDERS

Citation
Cg. Trolin et al., DECREASED METHIONINE ADENOSYLTRANSFERASE ACTIVITY IN ERYTHROCYTES OF PATIENTS WITH DEMENTIA DISORDERS, European neuropsychopharmacology, 5(2), 1995, pp. 107-114
Citations number
73
Categorie Soggetti
Neurosciences,"Pharmacology & Pharmacy
ISSN journal
0924977X
Volume
5
Issue
2
Year of publication
1995
Pages
107 - 114
Database
ISI
SICI code
0924-977X(1995)5:2<107:DMAAIE>2.0.ZU;2-7
Abstract
ATP:l-methionine S-adenosyltransferase (EC 2.5.1.6, MAT) activity was analyzed in erythrocytes from nine patients with a clinical diagnosis of probable Alzheimer's disease (Pro.AD), four with possible Alzheimer 's disease (Pos.AD), three with mild cognitive dysfunction (MCD) and t wo with dementia of vascular origin (VD), and 10 age-matched control s ubjects. Significantly lower kinetic parameters (V-max and K-m towards methionine) for MAT were observed in all the dementia cases. In the s ubgroup of Pro.AD patients who also had low plasma levels of vitamin B -12 (B-12), the reduction in MAT K-m was significantly correlated with an increase in the serum levels of homocysteine, while no such correl ation was observed in all the other dementia groups. Treatment for 6 m onths of this subgroup of Pro.AD patients with B-12 (1 mg x 7 days + 1 mg/week, i.m.), S-adenosylmethionine (SAM, 200 mg twice daily, p.o.) and folate (2.5 mg every 2 days, p.o.) caused a significant decrease i n homocysteine in parallel with a significant increase in K-m for MAT. These findings support the hypothesis that aberrations in the B-12 de pendent transmethylation reactions might be involved in the pathogenes is of dementia, and suggest that the evaluation of erythrocyte MAT act ivity may be a useful marker for the detection of such an aberration.